{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:05:48Z","timestamp":1779293148422,"version":"3.51.4"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T00:00:00Z","timestamp":1616025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Xcovery"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s10637-021-01093-7","type":"journal-article","created":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T19:38:11Z","timestamp":1616096291000},"page":"1298-1305","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Vorolanib (X-82), an oral anti-VEGFR\/PDGFR\/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2793-6901","authenticated-orcid":false,"given":"Katrina S.","family":"Pedersen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick M.","family":"Grierson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Picus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Craig","family":"Lockhart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce J.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley","family":"Morton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jesse","family":"Huffman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Wang-Gillam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,3,18]]},"reference":[{"issue":"15","key":"1093_CR1","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","volume":"16","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Hutson TE, Glen H, Michaelson MD, Molina A, Eisen T, Jassem J, Zolnierek J, Maroto JP, Mellado B, Melichar B, Tomasek J, Kremer A, Kim HJ, Wood K, Dutcus C, Larkin J (2015) Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 16(15):1473\u20131482. https:\/\/doi.org\/10.1016\/S1470-2045(15)00290-9","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"1093_CR2","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1097\/SCS.0b013e3181927e8a","volume":"20","author":"MM Cohen Jr","year":"2009","unstructured":"Cohen MM Jr (2009) Judah Folkman, MD, 1933-2008: father of angiogenesis. J Craniofac Surg 20(Suppl 1):590\u2013591. https:\/\/doi.org\/10.1097\/SCS.0b013e3181927e8a","journal-title":"J Craniofac Surg"},{"issue":"2","key":"1093_CR3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/S1535-6108(02)00031-4","volume":"1","author":"M Inoue","year":"2002","unstructured":"Inoue M, Hager JH, Ferrara N, Gerber HP, Hanahan D (2002) VEGF-A has a critical, nonredundant role in angiogenic switching and pancreatic beta cell carcinogenesis. Cancer Cell 1(2):193\u2013202","journal-title":"Cancer Cell"},{"issue":"7","key":"1093_CR4","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1097\/01.MP.0000077416.68489.50","volume":"16","author":"DE Hansel","year":"2003","unstructured":"Hansel DE, Rahman A, Hermans J, de Krijger RR, Ashfaq R, Yeo CJ, Cameron JL, Maitra A (2003) Liver metastases arising from well-differentiated pancreatic endocrine neoplasms demonstrate increased VEGF-C expression. Mod Pathol 16(7):652\u2013659. https:\/\/doi.org\/10.1097\/01.MP.0000077416.68489.50","journal-title":"Mod Pathol"},{"issue":"4","key":"1093_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","volume":"8","author":"O Casanovas","year":"2005","unstructured":"Casanovas O, Hicklin DJ, Bergers G, Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8(4):299\u2013309. https:\/\/doi.org\/10.1016\/j.ccr.2005.09.005","journal-title":"Cancer Cell"},{"issue":"8","key":"1093_CR6","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1200\/JCO.2007.13.6374","volume":"26","author":"JC Yao","year":"2008","unstructured":"Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA (2008) Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 26(8):1316\u20131323. https:\/\/doi.org\/10.1200\/JCO.2007.13.6374","journal-title":"J Clin Oncol"},{"issue":"33","key":"1093_CR7","doi-asserted-by":"publisher","first-page":"5422","DOI":"10.1200\/JCO.2008.16.9847","volume":"26","author":"BI Rini","year":"2008","unstructured":"Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26(33):5422\u20135428. https:\/\/doi.org\/10.1200\/JCO.2008.16.9847","journal-title":"J Clin Oncol"},{"issue":"13","key":"1093_CR8","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1200\/JCO.2009.26.7849","volume":"28","author":"B Escudier","year":"2010","unstructured":"Escudier B, Bellmunt J, Negrier S, Bajetta E, Melichar B, Bracarda S, Ravaud A, Golding S, Jethwa S, Sneller V (2010) Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 28(13):2144\u20132150. https:\/\/doi.org\/10.1200\/JCO.2009.26.7849","journal-title":"J Clin Oncol"},{"issue":"4","key":"1093_CR9","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1093\/annonc\/mdi113","volume":"16","author":"S Vignot","year":"2005","unstructured":"Vignot S, Faivre S, Aguirre D, Raymond E (2005) mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16(4):525\u2013537. https:\/\/doi.org\/10.1093\/annonc\/mdi113","journal-title":"Ann Oncol"},{"issue":"6","key":"1093_CR10","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","volume":"168","author":"RA Saxton","year":"2017","unstructured":"Saxton RA, Sabatini DM (2017) mTOR signaling in growth, metabolism, and disease. Cell 168(6):960\u2013976. https:\/\/doi.org\/10.1016\/j.cell.2017.02.004","journal-title":"Cell"},{"issue":"9637","key":"1093_CR11","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grunwald V, Thompson JA, Figlin RA, Hollaender N, Urbanowitz G, Berg WJ, Kay A, Lebwohl D, Ravaud A, Group R-S (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449\u2013456. https:\/\/doi.org\/10.1016\/S0140-6736(08)61039-9","journal-title":"Lancet"},{"key":"1093_CR12","doi-asserted-by":"publisher","unstructured":"Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K, Rad001 in Advanced Neuroendocrine Tumors TTSG (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364 (6):514\u2013523. doi:https:\/\/doi.org\/10.1056\/NEJMoa1009290","DOI":"10.1056\/NEJMoa1009290"},{"issue":"32","key":"1093_CR13","doi-asserted-by":"publisher","first-page":"3906","DOI":"10.1200\/JCO.2016.68.0702","volume":"34","author":"JC Yao","year":"2016","unstructured":"Yao JC, Pavel M, Lombard-Bohas C, Van Cutsem E, Voi M, Brandt U, He W, Chen D, Capdevila J, de Vries EGE, Tomassetti P, Hobday T, Pommier R, Oberg K (2016) Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study. J Clin Oncol 34(32):3906\u20133913. https:\/\/doi.org\/10.1200\/JCO.2016.68.0702","journal-title":"J Clin Oncol"},{"issue":"4","key":"1093_CR14","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1634\/theoncologist.2018-0740","volume":"24","author":"JC Bendell","year":"2019","unstructured":"Bendell JC, Patel MR, Moore KN, Chua CC, Arkenau HT, Dukart G, Harrow K, Liang C (2019) Phase I, first-in-human, dose-escalation study to evaluate the safety, tolerability, and pharmacokinetics of Vorolanib in patients with advanced solid tumors. Oncologist 24(4):455\u2013e121. https:\/\/doi.org\/10.1634\/theoncologist.2018-0740","journal-title":"Oncologist"},{"issue":"7","key":"1093_CR15","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1002\/cncr.26429","volume":"118","author":"AM Molina","year":"2012","unstructured":"Molina AM, Feldman DR, Voss MH, Ginsberg MS, Baum MS, Brocks DR, Fischer PM, Trinos MJ, Patil S, Motzer RJ (2012) Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma. Cancer 118(7):1868\u20131876. https:\/\/doi.org\/10.1002\/cncr.26429","journal-title":"Cancer"},{"issue":"4","key":"1093_CR16","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.clgc.2013.11.020","volume":"12","author":"RL Bitting","year":"2014","unstructured":"Bitting RL, Healy P, Creel PA, Turnbull J, Morris K, Wood SY, Hurwitz HI, Starr MD, Nixon AB, Armstrong AJ, George DJ (2014) A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 12(4):241\u2013250. https:\/\/doi.org\/10.1016\/j.clgc.2013.11.020","journal-title":"Clin Genitourin Cancer"},{"issue":"14","key":"1093_CR17","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1200\/JCO.2014.56.2082","volume":"33","author":"TJ Hobday","year":"2015","unstructured":"Hobday TJ, Qin R, Reidy-Lagunes D, Moore MJ, Strosberg J, Kaubisch A, Shah M, Kindler HL, Lenz HJ, Chen H, Erlichman C (2015) Multicenter phase II trial of Temsirolimus and Bevacizumab in pancreatic neuroendocrine tumors. J Clin Oncol 33(14):1551\u20131556. https:\/\/doi.org\/10.1200\/JCO.2014.56.2082","journal-title":"J Clin Oncol"},{"issue":"2","key":"1093_CR18","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1097\/MPA.0000000000000255","volume":"44","author":"JC Yao","year":"2015","unstructured":"Yao JC, Phan AT, Hess K, Fogelman D, Jacobs C, Dagohoy C, Leary C, Xie K, Ng CS (2015) Perfusion computed tomography as functional biomarker in randomized run-in study of bevacizumab and everolimus in well-differentiated neuroendocrine tumors. Pancreas 44(2):190\u2013197. https:\/\/doi.org\/10.1097\/MPA.0000000000000255","journal-title":"Pancreas"},{"key":"1093_CR19","doi-asserted-by":"publisher","first-page":"102755","DOI":"10.1016\/j.ebiom.2020.102755","volume":"55","author":"X Sheng","year":"2020","unstructured":"Sheng X, Yan X, Chi Z, Cui C, Si L, Tang B, Li S, Mao L, Lian B, Wang X, Bai X, Zhou L, Kong Y, Dai J, Ding L, Mao L, Guo J (2020) Phase 1 trial of vorolanib (CM082) in combination with everolimus in patients with advanced clear-cell renal cell carcinoma. EBioMedicine 55:102755. https:\/\/doi.org\/10.1016\/j.ebiom.2020.102755","journal-title":"EBioMedicine"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01093-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-021-01093-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-021-01093-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:08:06Z","timestamp":1678511286000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-021-01093-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,18]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["1093"],"URL":"https:\/\/doi.org\/10.1007\/s10637-021-01093-7","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,18]]},"assertion":[{"value":"11 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. The study was approved by the Institutional Review Boards of Washington University in St. Louis and Vanderbilt University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Patients signed informed consent regarding publishing their data and imaging.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"C.L.: Xcovery employee. No other relevant conflicts of interest to report by other authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}